Disclosed is a liquid aqueous formulation for the intranasal administration of apomorphine, which comprises: (a) at least about 15 mg/ml of apomorphine； and (b) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer) as a solubilising agent, wherein the poloxamer has an average molecular mass of 9,700 Da or less and has the general formula: HO(C2H4O)a(C3H6O)b(C2H4O)aH, wherein a is from 2 to 90 and b is from 15 to 40 for the treatment and/or management of Parkinson's disease or a medicament for the treatment and/or management of erectile dysfunction.
